Combination of PD-1 Checkpoint Blockade and Botulinum Toxin Type A1 Improves Antitumor Responses in Mouse Tumor Models of Melanoma and Colon Carcinoma.
Seong-Sung KwakJi-Young LeeMin Ju KimHyo Jin LeeDong-Kyu LeeJiyeon KangWon-Ho KangWoo-Chan SonDeu John M CruzPublished in: Immunological investigations (2023)
Our findings demonstrate the synergistic antitumor effects of BoNT/A1 and PD-1 checkpoint blockade in mouse tumor models of melanoma and colon carcinoma. These findings provide some evidence on the potential application of BoNT/A1 as an anticancer drug in combination with immune checkpoint blockade and should be further explored.